Singapore markets close in 2 hours 42 minutes
  • Straits Times Index

    3,163.89
    -20.65 (-0.65%)
     
  • Nikkei

    29,565.68
    -202.38 (-0.68%)
     
  • Hang Seng

    28,391.38
    -307.42 (-1.07%)
     
  • FTSE 100

    6,915.75
    -26.47 (-0.38%)
     
  • BTC-USD

    60,176.82
    +290.79 (+0.49%)
     
  • CMC Crypto 200

    1,286.99
    +59.45 (+4.84%)
     
  • S&P 500

    4,128.80
    +31.63 (+0.77%)
     
  • Dow

    33,800.60
    +297.00 (+0.89%)
     
  • Nasdaq

    13,900.19
    +70.89 (+0.51%)
     
  • Gold

    1,738.90
    -5.90 (-0.34%)
     
  • Crude Oil

    59.02
    -0.30 (-0.51%)
     
  • 10-Yr Bond

    1.6660
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,606.52
    -5.73 (-0.36%)
     
  • Jakarta Composite Index

    5,989.06
    -81.15 (-1.34%)
     
  • PSE Index

    6,518.64
    -26.53 (-0.41%)
     

Worldwide End Stage Renal Disease Industry to 2025 - High Focus on Technology Presents Opportunities - ResearchAndMarkets.com

·4-min read

The "Global End Stage Renal Disease Market (2020-2025) by Disease Type, Treatment Type, End User, Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

The global end stage renal disease market is estimated to be USD 73.1 billion in 2020 and is expected to reach USD 137.08 billion by 2025, growing at a CAGR of 13.4 %.

The increasing number of patients suffering from kidney failure and the introduction of technologically advanced products, such as low maintenance dialysis equipment and artificial kidney, are the major factors expected to drive the end stage renal disease (ESRD) market. The ongoing Covid-19 pandemic has resulted in an increased demand for home dialysis across the globe.

Companies Mentioned

  • Nipro Corporation

  • Fresenius Medical Care AG & Co. KGaA

  • Baxter International, Inc.

  • Medtronic Plc

  • B. Braun Melsungen AG

  • BD

  • Asahi Kasei Medical Co., Ltd.

  • Cantel Medical

  • Nikkiso Co., Ltd.

  • JMS Co. Ltd.

  • Abbott

  • Amgen Inc.

  • AstraZeneca

  • Bristol-Myers Squibb Company

  • F. Hoffmann-La Roche Ltd

  • Fresenius Medical Care AG & Co.

  • GlaxoSmithKline PLC

  • Keryx Biopharmaceuticals, Inc

  • Kissei Pharmaceutical Co., Ltd

  • Novartis AG

  • Pfizer Inc.

  • Sanofi SA

  • Teva Pharmaceutical Industries Ltd

Competitive Quadrant

The report includes the Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global End Stage Renal Disease Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.

  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.

  • The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.

  • The report also contains the competitive analysis using IGR Competitive Quadrant, the analyst's proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry

  • Important market dynamics and trends

  • Market segmentation

  • Historical, current, and projected size of the market based on value and volume

  • Market shares and strategies of key players

  • Recommendations to companies for strengthening their foothold in the market

Key Topics Covered:

1 Report Description

1.1 Study Objectives

1.2 Market Definition

1.3 Currency

1.4 Years Considered

1.5 Language

1.6 Key Stakeholders

2 Research Methodology

2.1 Research Process

2.2 Data Collection and Validation

2.2.1 Secondary Research

2.2.2 Primary Research

2.3 Market Size Estimation

2.4 Assumptions of the Study

2.5 Limitations of the Study

3 Executive Summary

4 Market Overview

4.1 Introduction

4.2 Market Dynamics

4.2.1 Drivers

4.2.1.1 Growing prevalence of diabetes and hypertension

4.2.1.2 Introduction of technologically advanced products

4.2.1.3 Increasing number of patients suffering from chronic kidney disease

4.2.2 Restraints

4.2.2.1 Risk of complications

4.2.2.2 Stringent regulatory policies for dialysis products

4.2.3 Opportunities

4.2.3.1 High Focus on technology

4.2.3.2 R&D

4.2.4 Challenges

4.2.4.1 Lack of infrastructure availability in emerging countries

4.3 Trends

5 Market Analysis

5.1 Porter's Five Forces Analysis

5.2 Impact of COVID-19

5.3 Ansoff Matrix Analysis

6 Global End Stage Renal Disease Market, By Disease Type

6.1 Chronic Kidney Disease

6.2 End-Stage Renal Disease (ESRD)

7 Global End Stage Renal Disease Market, By Treatment Type

7.1 Dialysis

7.2 Medication

7.3 Kidney Transplantation

8 Global End Stage Renal Disease Market, By End Users

8.1 Dialysis Centres

8.2 Hospital & Clinics

8.3 Research and Academic Institutes

9 Global End Stage Renal Disease Market, By Geography

9.1 Introduction

9.2 North America

9.3 South America

9.4 Europe

9.5 Asia-Pacific

9.6 Rest of the World

10 Competitive Landscape

10.1 IGR Competitive Quadrant

10.2 Market Share Analysis

10.3 Competitive Scenario

10.3.1 Mergers & Acquisitions

10.3.2 Agreement, Collaborations, & Partnerships

10.3.3 New Product Launches & Enhancements

10.3.4 Investments & Funding

11 Company Profiles

12 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/hhsy3i

View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005533/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900